Study links inflammation levels to outcomes in MPN patients
Part of Blood & lymphatic clinical trials.
This study looks at inflammation-related lab markers in people with “Ph-negative” myeloproliferative neoplasms (like PV, ET, or PMF) to see how they relate to outcomes and response to treatment. It’s observational, meaning it gathers information from medical records without testing a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older at the time your myeloproliferative neoplasm (MPN) was diagnosed
- Have a Ph-negative MPN diagnosis such as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF), or develop myelofibrosis after PV/ET
- Your diagnosis must have been made since the year 2000
- You must be able to provide informed consent (agree to join the study)
- You should not have a life expectancy under 6 months
- You should not have accelerated-phase myelofibrosis or MPN that shows signs of moving toward leukemia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
This study looks at heart and blood vessel problems in people with certain blood cancers called myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and primary myelofibrosis. It aims to understand how these conditions affect the heart and blood vessels, which may lead to better care.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
Hear when a new Myeloproliferative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.